Three-Hour Paclitaxel Infusion and Carboplatin Is an Effective Outpatient Treatment for Stage III Epithelial Ovarian Cancer
Authors:
- 28 February 1998
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 68 (2) , 166-168
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study.Journal of Clinical Oncology, 1997
- Paclitaxel Delivered as a 3-hr Infusion with Cisplatin in Patients with Gynecologic Cancers: Unexpected Incidence of NeurotoxicityGynecologic Oncology, 1996
- Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.Journal of Clinical Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.Journal of Clinical Oncology, 1994
- Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.Journal of Clinical Oncology, 1992
- Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1992
- Sequences of taxol and cisplatin: a phase I and pharmacologic study.Journal of Clinical Oncology, 1991
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- Creatinine Clearance: Bedside EstimateAnnals of Internal Medicine, 1973